title: Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
abstract: Rimonabant is a cannabinoid type 1 receptor (CB1) antagonist formerly used to treat obesity, but which was withdrawn from the market in late 2008 because of its association with psychiatric adverse effects such as depression and anxiety. Previously, we showed that a single dose of rimonabant produced a negative bias on an emotional word memory task, in the absence of subjective mood effects. The present study investigated whether a similar effect on emotional processing could be seen after 7 days' daily treatment with rimonabant 20 mg, using a randomized, placebo-controlled, between-subjects design in healthy volunteers (final n = 21). In comparison with placebo, rimonabant induced a negative bias on a memory recognition task without producing a change in subjective mood. This raises the possibility that the depressogenic effects of rimonabant may be linked to emotional memory biases, and that such biases may be detectable in the absence of subjective mood changes. Investigating such effects could be useful in detecting adverse psychiatric effects of novel treatments.
authors.affiliation: University Department of Psychiatry, Neurosciences Building, Warneford Hospital, Oxford, UK. jamie.horder@googlemail.com
authors.forename: Jamie
authors.initials: J
authors.lastname: Horder
authors.forename: Michael
authors.initials: M
authors.lastname: Browning
authors.forename: Martina
authors.initials: M
authors.lastname: Di Simplicio
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Cowen
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Harmer
mesh_terms: D000328:Adult; D001008:Anxiety Disorders / Q000139:chemically induced / Q000378:metabolism; D003863:Depression / Q000139:chemically induced / Q000378:metabolism; D004644:Emotions / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology*; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D021641:Recognition, Psychology / Q000187:drug effects; D000077285:Rimonabant; D055815:Young Adult
chemical_list: D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant